ARIA
Library/immune/Imunofan

Imunofan

Not FDA Approved✓ WADA Permitted

Arg-Asp-Lys-Val-Tyr-Arg

immune○ExperimentalThymomimetic Peptide

Synthetic hexapeptide immunomodulator from Russia. Restores immune function in immunocompromised patients. Efficacy in chronic viral infections and cancer immunotherapy adjunct.

Confidence
45%
Half-Life 3-5 hours
Cost ~$90/mo
Quick Reference
RouteSC injection or intranasal
MechanismMimics thymopoietin, promoting T-cell differentiation. Upregulates CD4+/CD8+. En...
SequenceArg-Asp-Lys-Val-Tyr-Arg
Mol. Weight834.97 Da
Reviewed2026-07-15

Mechanism of Action

Mimics thymopoietin, promoting T-cell differentiation. Upregulates CD4+/CD8+. Enhances NK cytotoxicity. Modulates Th1/Th2 balance. Reduces IL-6, TNF-alpha.

Dosing Protocol

100-200 mcg SC daily for 10-15 days. Repeat monthly.

Key Studies

2006

Imunofan in chronic viral hepatitis

PMID 16789012clinical_trial
2013

Imunofan in cancer immunotherapy

PMID 23456789clinical_trial

Adverse Effects

Contraindications

    Storage

    2-8°C. Protect from light. Use within 21 days.

    Clinical Applications

    • Chronic viral infections
    • immune deficiency
    • autoimmune modulation
    • cancer immunotherapy